LINFOMAS Y TRASPLANTES
Dana–Farber Cancer Institute
Boston, Estados UnidosPublications en collaboration avec des chercheurs de Dana–Farber Cancer Institute (5)
2023
2019
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204